KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Boston Scientific (BSX) Free Cash Flow (2016 - 2025)

Boston Scientific (BSX) has disclosed Free Cash Flow for 17 consecutive years, with $1.0 billion as the latest value for Q4 2025.

  • Quarterly Free Cash Flow fell 14.08% to $1.0 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.7 billion through Dec 2025, up 38.3% year-over-year, with the annual reading at $3.7 billion for FY2025, 38.3% up from the prior year.
  • Free Cash Flow hit $1.0 billion in Q4 2025 for Boston Scientific, down from $1.2 billion in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $1.2 billion in Q4 2024 to a low of -$179.0 million in Q1 2022.
  • Historically, Free Cash Flow has averaged $517.4 million across 5 years, with a median of $511.5 million in 2023.
  • Biggest five-year swings in Free Cash Flow: plummeted 185.65% in 2022 and later surged 2460.0% in 2025.
  • Year by year, Free Cash Flow stood at $212.0 million in 2021, then surged by 180.66% to $595.0 million in 2022, then rose by 15.97% to $690.0 million in 2023, then skyrocketed by 70.87% to $1.2 billion in 2024, then decreased by 14.08% to $1.0 billion in 2025.
  • Business Quant data shows Free Cash Flow for BSX at $1.0 billion in Q4 2025, $1.2 billion in Q3 2025, and $1.1 billion in Q2 2025.